Merck Reports Phase 3 TroFuse-005 Trial Shows Sac-TMT Improves Overall And Progression-Free Survival, Meeting Both Dual Primary And Key Secondary Endpoints Of ORR In Advanced Or Recurrent Endometrial Cancer; FDA Priority Review Accepted
TroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who have received prior
Merck's new cancer medicine worked better than old treatment in testing. The FDA is fast tracking it, which suggests they think it could help patients soon.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.